Vaxxinity stock holds at penny level as investors watch recent vaccine data

Published on 09/18/2026 at 15:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxxinity stock traded around USD 0.06 in mid September 2026, keeping the company in penny-stock territory despite its vaccine platform. Recent interim results and pipeline updates give investors fresh figures to assess the biotech’s prospects.

VAXX, US92239B1035, Illustration mit AI erstellt.

Vaxxinity stock (ISIN US92239B1035) is trading around USD 0.06 as of mid September 2026, leaving the Dallas based biotech firmly in penny stock territory while investors weigh its vaccine platform’s longer term potential.

Small market value and thin trading

On September 18, 2026, recent quote data on a global stock portal showed Vaxxinity shares changing hands at about USD 0.055, highlighting the very low absolute price level for the stock and the speculative nature of the position for retail investors.

With only around a few hundred shares reported as having traded in that snapshot and a micro market capitalization derived from the sub USD 0.10 share price, Vaxxinity’s equity currently offers limited liquidity compared with large vaccine peers, which is an important practical factor for investors considering entry or exit.

Most recent reported figures and pipeline context

According to Vaxxinity’s own investor relations materials available via its corporate site, the company most recently reported interim financial figures for the first half of 2026, including revenue and operating loss metrics that reflect continued investment in its vaccine pipeline and platform rather than established commercial scale.

In that latest half year report for the period ended June 30, 2026, management outlined research and development spending alongside cash and cash equivalent balances, giving investors an updated view of how long the company can fund clinical development at the current burn rate.

Comparison with larger vaccine makers

For context, some portals in mid September 2026 highlighted price action in larger vaccine developers and their fundamentals, underscoring the contrast between Vaxxinity’s micro capitalisation status and the multi billion dollar market values of established players in the COVID 19 and broader vaccine space.

Historical financial statement overviews for other health care issuers show quarterly revenues in the tens of millions of local currency units through Q2 2026 and net profits also in the low millions, illustrating how far a pre commercial company like Vaxxinity still has to go to reach similar scale.

Stock price remains highly speculative

Given the sub USD 0.10 share price as of September 18, 2026 and thin trading volume reported in available quote data, Vaxxinity stock currently carries the characteristics of a highly speculative clinical stage biotech investment rather than a mature cash generating business.